We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B Turnover 46.34%
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+19.03%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$4.08B
AUM Growth
+$976M
Cap. Flow
+$264M
Cap. Flow %
6.47%
Top 10 Hldgs %
75.07%
Holding
69
New
11
Increased
11
Reduced
6
Closed
16
Avg Time Held Equity + Options
1.5 years
Top 10 Avg Time Held Equity + Options
2.1 years
Top 20 Avg Time Held Equity + Options
1.8 years
Avg Time Held Equity only
1.6 years
Top 10 Avg Time Held Equity only
2.1 years
Top 20 Avg Time Held Equity only
1.8 years

Top Buys

Rank Stock Value
1
BPMC icon
Blueprint Medicines
BPMC
+$97.8M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$85.3M
3
LKFT icon
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$61.7M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$49.6M
5
RVMD icon
Revolution Medicines
RVMD
+$45.3M

Top Sells

Rank Stock Value
1
JANX icon
Janux Therapeutics
JANX
+$45.3M
2
KYMR icon
Kymera Therapeutics
KYMR
+$23.6M
3
ACET icon
Adicet Bio
ACET
+$20.5M
4
DYN icon
Dyne Therapeutics
DYN
+$18M
5
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 92.91%
2 Miscellaneous 7.09%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
KRON icon
51
DELISTED
Kronos Bio
KRON
$562K 0.01%
326,780
– –
2020 Q4
10 quarters
CMAXW icon
52
DELISTED
CareMax, Inc. Warrant
CMAXW
$311K 0.01%
100,000
– –
2020 Q4
10 quarters
SRZNW icon
53
DELISTED
Surrozen Inc Warrant
SRZNW
$36.7K ﹤0.01%
66,665
– –
2021 Q2
8 quarters
ACET icon
54
Adicet Bio
ACET
$42.8M
– –
-222,544
Closed -$20.5M –
ARQT icon
55
Arcutis Biotherapeutics
ARQT
$3.62B
– –
-415,322
Closed -$4.57M –
BDTX icon
56
Black Diamond Therapeutics
BDTX
$98.8M
– –
-1,191,094
Closed -$2.25M –
BEAM icon
57
Beam Therapeutics
BEAM
$2.42B
– –
-198,591
Closed -$6.08M –
CGEM icon
58
Cullinan Oncology
CGEM
$832M
– –
-246,410
Closed -$2.52M –
ERAS icon
59
Erasca
ERAS
$4.68B
– –
-678,441
Closed -$2.04M –
ITOS icon
60
DELISTED
iTeos Therapeutics
ITOS
– –
-1,300
Closed -$17.7K –
KYMR icon
61
Kymera Therapeutics
KYMR
$8.71B
– –
-796,093
Closed -$23.6M –
MGNX icon
62
MacroGenics
MGNX
$207M
– –
-619,192
Closed -$4.44M –
RNAC icon
63
Cartesian Therapeutics
RNAC
$190M
– –
-6,667
Closed -$278K –
CYT
64
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
– –
-43,823
Closed -$79.8K –
GRCL
65
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
– –
-798,948
Closed -$1.49M –
SURF
66
DELISTED
Surface Oncology, Inc. Common Stock
SURF
– –
-3,082,959
Closed -$2.15M –
KDNY
67
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-445,550
Closed -$10.3M –
EUCRW
68
DELISTED
Eucrates Biomedical Acquisition Corp. Warrant
EUCRW
– –
-66,666
Closed -$676K –
EUCR
69
DELISTED
Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
– –
-200,000
Closed -$2.03M –
1 2
3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q2 2023 Portfolio in Review

As of Q2 2023, EcoR1 Capital held 69 positions worth $4.08B, up 31% from $3.11B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

EcoR1 Capital deployed $264M of net new capital in Q2 2023, opening 11 new positions and adding to 11 existing holdings. Its largest new stake was Blueprint Medicines: 1,798,300 shares worth $114M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 100% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Janux Therapeutics, an estimated $45.3M trimmed.

  • EcoR1 Capital's largest Q2 2023 buy was Blueprint Medicines: 1,798,300 shares worth $114M.
  • EcoR1 Capital added most to Sarepta Therapeutics in Q2 2023, an estimated $85.3M increase.
  • EcoR1 Capital's biggest Q2 2023 reduction was Janux Therapeutics, cutting an estimated $45.3M.
  • EcoR1 Capital fully exited Kymera Therapeutics in Q2 2023, selling an estimated $23.6M.
  • EcoR1 Capital's ten largest holdings make up 75% of its $4.08B portfolio in Q2 2023.
  • EcoR1 Capital opened 11 new positions and closed 16 in Q2 2023.
  • EcoR1 Capital's portfolio value rose 31% quarter-over-quarter to $4.08B.

Based on EcoR1 Capital's 13F filing for Q2 2023, filed 14 Aug 2023.